Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on March 23, 2022. The filing serves to announce the Company's results of operations for the fiscal year ended December 31, 2021. The Company is listed on The Nasdaq Capital Market.
Financial Metrics
This Form 8-K is a notification of results and does not contain specific financial data points within the text provided. The filing references a press release (Exhibit 99.1) for detailed figures. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. The filing text does not provide a clear value for these metrics.
Material Changes
The filing does not detail specific material changes or comparative financial data versus the prior period. It solely indicates that the results for the fiscal year ended December 31, 2021, have been announced via a press release.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific financial results for the fiscal year ended December 31, 2021, by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the Company's liquidity position and cash burn rate, as this 8-K does not disclose current cash balances or debt obligations.
- Note that James Martin serves as both Chief Financial Officer and Co-Interim Chief Executive Officer.
- Review the full text of the press release for any updates on clinical trials or product development, as this 8-K only announces the release of results.